Cargando…
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers
HER2-positive breast cancer has long proven to be a clinically distinct class of breast cancers for which several targeted therapies are now available. However, resistance to the treatment associated with specific gene expressions or mutations has been observed, revealing the underlying diversity of...
Ejemplares similares
-
Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
por: Sertier, Anne-Sophie, et al.
Publicado: (2023) -
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients
por: Cox, David G., et al.
Publicado: (2016) -
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes
por: Curtit, Elsa, et al.
Publicado: (2017) -
Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort
por: Pivot, Xavier, et al.
Publicado: (2017) -
An Early Neoplasia Index (ENI10), Based on Molecular Identity of CD10 Cells and Associated Stemness Biomarkers, is a Predictor of Patient Outcome in Many Cancers
por: Guyot, Boris, et al.
Publicado: (2023)